Eribulin Mesylate For Injection

Product Description

Ebunat 0.5mg Injection is used in thetreatment of breast cancer. It is used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other anticancer medicines after the cancer has spread.

1. What is Eribulin Mesylate For Injection?

   • Eribulin mesylate for injection is a medication used to treat certain types of cancer, including metastatic breast cancer and liposarcoma. It belongs to a class of drugs called microtubule inhibitors, which work by disrupting the growth and division of cancer cells.

2. What conditions are treated with Eribulin Mesylate For Injection?

   • Eribulin mesylate is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. It is also approved for the treatment of unresectable or metastatic liposarcoma.

3. How is Eribulin Mesylate For Injection administered?

   • Eribulin mesylate is administered by intravenous (IV) infusion over a specified period, usually on days 1 and 8 of a 21-day cycle. The dosage and schedule may vary depending on factors such as the type of cancer being treated and the patient's individual medical condition. Treatment is typically continued until disease progression or unacceptable toxicity occurs.

4. What are the possible side effects of Eribulin Mesylate For Injection?

   • Common side effects of eribulin mesylate may include fatigue, nausea, vomiting, constipation, peripheral neuropathy (numbness or tingling in the hands and feet), hair loss, and decreased appetite. More serious side effects can occur, including low blood cell counts (anemia, neutropenia), fever, infection, and allergic reactions. It's important to report any unusual symptoms to your doctor.

5. Can Eribulin Mesylate For Injection be used during pregnancy or breastfeeding?

   • Eribulin mesylate may cause harm to an unborn baby if used during pregnancy and is not recommended for use during pregnancy. It is also not recommended for use while breastfeeding as it may harm the nursing infant. Women of childbearing potential should use effective contraception during treatment and for a period of time after discontinuing the medication.

6. Are there any medications that interact with Eribulin Mesylate For Injection?

   • Eribulin mesylate may interact with certain medications, including other chemotherapy drugs and medications that affect liver function. It's essential to inform your doctor about all medications you are taking, including prescription, over-the-counter, and herbal supplements, to avoid potentially harmful interactions.

7. How should Eribulin Mesylate For Injection be stored?

   • Eribulin mesylate for injection should be stored as directed by the manufacturer. Typically, it should be stored at room temperature away from light and moisture. Keep the medication out of reach of children and pets. Check the expiration date and properly dispose of any expired medication.

 

Specialized Antineoplastic Agent for Hospital Use

Eribulin Mesylate For Injection is an advanced antineoplastic agent used exclusively in healthcare settings under medical supervision. It is indicated for metastatic breast cancer and unresectable liposarcoma, ensuring healthcare professionals have a reliable treatment option. The drug is supplied in a high-purity, lyophilized powder form, providing ready compatibility with standard intravenous infusion protocols and facilitating safe, controlled administration.


Easy Reconstitution and Administration

The product is conveniently supplied as a sterile, preservative-free powder, which must be reconstituted with 0.9% sodium chloride injection. This preparation results in a neutral pH (approximately 7.0) solution, compatible with standard IV infusion equipment. The ready-to-reconstitute feature streamlines administration by healthcare professionals, improving efficiency without compromising safety.